ENLIVEN THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ENLIVEN THERAPEUTICS, INC. (ELVN) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $13.91 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- ENLIVEN THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $13.91M, a 80.15% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $7.40M, a 8.80% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $7.18M, a 38.81% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $7.72M, a 50.16% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $34.02M, a 68.63% increase from fiscal 2024.
- ENLIVEN THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $20.17M, a 56.22% increase from fiscal 2023.
- ENLIVEN THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $12.91M, a 304.70% increase from fiscal 2022.
- ENLIVEN THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $3.19M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $13.91M 10-Q · filed 2026-08-05 | $21.31M derived: sum of 2 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $7.40M 10-Q · filed 2026-08-05 | |||||
| 2025-12-31 | $34.02M 10-K · filed 2026-03-03 | |||||
| 2025-09-30 | $7.18M 10-Q · filed 2025-11-12 | $14.91M derived: sum of 2 quarters · filed 2026-08-05 | $21.71M derived: sum of 3 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $7.72M 10-Q · filed 2026-08-05 | $14.52M derived: sum of 2 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $6.80M 10-Q · filed 2026-08-05 | |||||
| 2024-12-31 | $20.17M 10-K · filed 2026-03-03 | |||||
| 2024-09-30 | $5.18M 10-Q · filed 2025-11-12 | $10.32M derived: sum of 2 quarters · filed 2025-11-12 | $14.84M derived: sum of 3 quarters · filed 2025-11-12 | |||
| 2024-06-30 | $5.14M 10-Q · filed 2025-11-12 | $9.66M derived: sum of 2 quarters · filed 2025-11-12 | ||||
| 2024-03-31 | $4.51M 10-Q · filed 2025-11-12 | |||||
| 2023-12-31 | $12.91M 10-K · filed 2025-03-13 | |||||
| 2023-09-30 | $3.40M 10-Q · filed 2024-11-13 | $7.60M derived: sum of 2 quarters · filed 2024-11-13 | $9.86M derived: sum of 3 quarters · filed 2024-11-13 | |||
| 2023-06-30 | $4.20M 10-Q · filed 2024-11-13 | $6.46M derived: sum of 2 quarters · filed 2024-11-13 | ||||
| 2023-03-31 | $2.26M 10-Q · filed 2024-11-13 | |||||
| 2022-12-31 | $3.19M 10-K · filed 2024-03-14 | $2.60M 10-K · filed 2023-02-10 | ||||
| 2022-09-30 | $1.10M 10-Q · filed 2023-11-09 | $500.00K 10-Q · filed 2022-10-25 | $1.80M derived: sum of 2 quarters · filed 2023-11-09 | $2.46M derived: sum of 3 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $701.00K 10-Q · filed 2023-11-09 | $385.00K 10-Q · filed 2022-08-03 | $1.35M derived: sum of 2 quarters · filed 2023-11-09 | |||
| 2022-03-31 | $654.00K 10-Q · filed 2023-11-09 | $1.06M 10-Q · filed 2022-05-06 | ||||
| 2021-12-31 | $1.92M 8-K · filed 2023-06-23 | $3.85M 10-K · filed 2022-03-15 | ||||
| 2021-09-30 | $1.00M 10-Q · filed 2022-10-25 | $1.92M derived: sum of 2 quarters · filed 2022-10-25 | $2.87M derived: sum of 3 quarters · filed 2022-10-25 | |||
| 2021-06-30 | $917.00K 10-Q · filed 2022-10-25 | $1.86M derived: sum of 2 quarters · filed 2022-10-25 | ||||
| 2021-03-31 | $947.00K 10-Q · filed 2022-10-25 | |||||
| 2020-12-31 | $2.23M 10-K · filed 2022-03-15 | |||||
| 2020-09-30 | $642.00K 10-Q · filed 2021-11-09 | $1.19M derived: sum of 2 quarters · filed 2021-11-09 | $1.55M derived: sum of 3 quarters · filed 2021-11-09 | |||
| 2020-06-30 | $550.00K 10-Q · filed 2021-11-09 | $910.00K derived: sum of 2 quarters · filed 2021-11-09 | ||||
| 2020-03-31 | $360.00K 10-Q · filed 2021-11-09 | |||||
| 2019-12-31 | $899.00K 10-K · filed 2021-03-05 | |||||
| 2019-09-30 | $310.00K 10-Q · filed 2020-11-05 | $507.00K derived: sum of 2 quarters · filed 2020-11-05 | $602.00K derived: sum of 3 quarters · filed 2020-11-05 | |||
| 2019-06-30 | $197.00K 10-Q · filed 2020-11-05 | $292.00K derived: sum of 2 quarters · filed 2020-11-05 | ||||
| 2019-03-31 | $95.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |